Sexual Desire Problems in Women Seeking Healthcare: A Novel Study Design for Ascertaining Prevalence of Hypoactive Sexual Desire Disorder in Clinic-Based Samples of U.S. Women

Rosen, Raymond C.; Connor, Megan K.; Miyasato, G.; Link, Carol L.; Shifren, Jan L.; Fisher, William A.; Derogatis, Leonard R.; Schobelock, Michael J.

doi:10.1089/jwh.2011.3002

Cited by 32 publications

(23 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Rosen et al (2012) clinical sites by using FSFI, and reported its resulting sexual desire score of 1.9 from women with HSDD, which was showed to be similar to the sexual desire functioning in the present study's samples' score of 1.99.…”

Section: ⅳ Discussionsupporting

confidence: 75%

“…However, since the participants in the study mentioned above were younger than those of the present study with the average age of 45.6 years, we think their sexual function score was reported lower. When the participants' sexual desire score of the present research is compared with that of other researches with similar sample ages, Rosen et al (2012) measured the degree of sexual function in women with HSDD (mean age 46.7) and reported a sexual function score of 15.4, which is higher than the score of 14.7 in our study. Kim & Lee (2010) reported that, with a mean sexual function score of 20.6, 57.5% of married women complained of sexual dysfunction.…”

Section: ⅳ Discussioncontrasting

confidence: 53%

See 1 more Smart Citation

Sexual Desire, Sexual Function, and Quality of Life in Married Women with Hypoactive Sexual Desire Disorder

Kim

2013

Korean Journal of Health Education and Promotion

View full text Add to dashboard Cite

Objectives: This study was performed to identify the relationship among sexual desire, other domains of sexual function and quality of life (QOL) and to describe the effect of sexual desire on sexual function and QOL in married women with hypoactive sexual desire disorder (HSDD). Methods: A total of 397 women with HSDD participated in this study. Data were collected through self-reported questionnaire which were constructed to include general characteristics items, Female Sexual Function Index (FSFI), and QOL tool. Data were analyzed using SPSS/WIN20 for descriptive statistics, t-test, one-way ANOVA, Duncan, partial correlation coefficients, and Hierarchial multiple regression. Results: There were significant correlations with sexual desire and other domains of sexual function. And also, sexual desire had a positive correlations with the psychological status and total QOL. The sexual desire was statistically significant predictors for sexual function and QOL. Conclusions: Health professionals should direct efforts toward developing sexual health-related counseling or education programs for women suffering from sexual dysfunction with the goal of helping them to achieve satisfying sex lives and improved quality of life.

show abstract

Section: ⅳ Discussionsupporting

confidence: 75%

Section: ⅳ Discussioncontrasting

confidence: 53%

Sexual Desire, Sexual Function, and Quality of Life in Married Women with Hypoactive Sexual Desire Disorder

Kim

2013

Korean Journal of Health Education and Promotion

View full text Add to dashboard Cite

show abstract

“…Hypoactive sexual desire disorder (HSDD) is a common sexual dysfunction disorder, affecting up to 10% of women in the United States, [1][2][3] with similar prevalence worldwide. [4][5][6] HSDD is characterized by low sexual desire and associated distress.…”

Section: What Is Known and Objectivementioning

confidence: 99%

The pharmacodynamic effects of combined administration of flibanserin and alcohol

et al. 2017

View full text Add to dashboard Cite

SummaryWhat is known and objective: Flibanserin is a serotonin 5-HT 1A agonist and 5-HT 2A antagonist approved for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Because of the increased risk of hypotension-and syncope-related adverse events (AEs) observed with coadministration of flibanserin and alcohol, alcohol use is contraindicated. To provide a more comprehensive understanding of the interaction between flibanserin and alcohol, the results of a dedicated phase 1 alcohol-interaction study and a pooled analysis of phase 3 studies of premenopausal women with HSDD are presented. Methods: In the phase 1 study, healthy participants (males [n=23] and females [n=2])were randomly assigned to one of five sequence groups, which determined the order in which they were to receive flibanserin 100 mg or placebo, with or without ethanol 0.4 g/kg or 0.8 g/kg. Change from baseline in seated blood pressure, orthostatic vital signs, AEs and visual analogue scale sedation outcomes were examined. Blood samples were collected at baseline and for up to 4 hours after dosing to determine flibanserin area under the plasma concentration-time curve from 0 to 4 hours (AUC 0-4 ).Pooled data from five phase 3 studies of patients receiving flibanserin 100 mg once daily (n=1543), or placebo (n=1905), were analysed. Results:In the phase 1 study, the incidence of hypotension and syncope increased when flibanserin was coadministered with ethanol. Sedation increased 20% and 27% from baseline with flibanserin plus ethanol 0.4 g/kg and 0.8 g/kg, respectively, at 4 hours post-dose. In the pooled analysis of phase 3 studies, 58.2% and 63.6% of participants receiving flibanserin or placebo, respectively, reported baseline alcohol use. In patients receiving flibanserin, fatigue and dizziness occurred more frequently in patients with vs. without alcohol use. What is new and conclusion:Results from this study suggest that increased incidence of hypotension-and syncope-related events may result from a pharmacodynamic interaction between flibanserin and alcohol, although the clinical significance of these interactions in real-world populations remains unclear. K E Y W O R D Sadditive pharmacodynamic effects, central nervous system depression, ethanol, flibanserin, hypotension, syncopeThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

show abstract

“…The campaign fails to provide such information in many areas: (1) the treatment is falsely claimed to be as safe and effective as the treatments for males; (2) women are suggested as suffering from a medical condition with an identifiable biological background. As we demonstrated, this can at most be treated as one hypothetical factor among many others, while health-related or stress-related, psychological and relational factors are proven to be responsible for diminished sexual desire and accompanied distress in the majority of women;10 (3) the data about the other factors are not enumerated; (4) as a result, the availability of alternative, potentially effective and less intrusive treatments is not presented.…”

Section: The Campaignmentioning

confidence: 99%

The unethical use of ethical rhetoric: the case of flibanserin and pharmacologisation of female sexual desire

Chańska

Grunt-Mejer

2016

J Med Ethics

View full text Add to dashboard Cite

The current debate around sexual dysfunctions focuses mostly on the pharmacological regulation of lowered sexual desire in women. The Food and Drug Administration approval of the first drug-Addyi-to treat this condition was preceded by a campaign, in which ethically saturated arguments were used to lobby policy makers. This article provides a critical evaluation of these arguments. In particular, we focus our attention on deceitful and unethical use of moral arguments and concepts. First, we present the context in which hypoactive sexual desire disorder is defined as a serious medical condition, showing how non-medical and non-scientific influences shaped the understanding of the problem. Further, we demonstrate how in current discussions regarding lower sexual interest attention has been shifted from psychosocial to pharmacological solutions and we trace the ethical consequences of such a change. We argue that, in addition to typical detrimental effects of overmedicalisation, there are new serious perils. In particular, we demonstrate that it is highly probable that pharmacologisation of female desire-contrary to the emancipatory declarations of the drug proponents-exerts pressure on women and narrows the range of potential choices they can make. As a result, it is inconsistent with the very idea of free choice.

show abstract

Sexual Desire Problems in Women Seeking Healthcare: A Novel Study Design for Ascertaining Prevalence of Hypoactive Sexual Desire Disorder in Clinic-Based Samples of U.S. Women

Abstract: In this sample of women recruited in the clinical care setting, we observed an overall prevalence rate of 7.4% of acquired, generalized HSDD, with markedly increased prevalence in midlife women.

Cited by 32 publications

References 25 publications

Sexual Desire, Sexual Function, and Quality of Life in Married Women with Hypoactive Sexual Desire Disorder

Sexual Desire, Sexual Function, and Quality of Life in Married Women with Hypoactive Sexual Desire Disorder

The pharmacodynamic effects of combined administration of flibanserin and alcohol

The unethical use of ethical rhetoric: the case of flibanserin and pharmacologisation of female sexual desire

Contact Info

Product

Resources

About